Pavel Artemov

Pavel studies mechanisms underpinning drug resistance in lymphoma. In a rare intersection, he combines computational and laboratory approaches in his research. Previously, Pavel conducted commercial due diligence and strategy analysis for private equity funds as a freelancer and as a consultant at Candesic. Pavel holds MSci in Systems Biology and BA in Biochemistry from University of Cambridge.